Cas:10025-99-7 Potassium tetrachloroplatinate(II) manufacturer & supplier

We serve Chemical Name:Potassium tetrachloroplatinate(II) CAS:10025-99-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Potassium tetrachloroplatinate(II)

Chemical Name:Potassium tetrachloroplatinate(II)
CAS.NO:10025-99-7
Synonyms:EINECS 233-050-9;dipotassium,tetrachloroplatinum(2-);Dipotassium tetrachloroplatinate(2-);Potassium platinochloride;Platinate(2-), tetrachloro-, potassium (1:2);Potassium tetrachloroplatinate;Platinous potassium chloride;Potasium tetrachloroplatinate (I);Potassium tetrachloroplatinate(II);Potassium chloroplatinite;MFCD00011378
Molecular Formula:Cl4K2Pt
Molecular Weight:415.08700
HS Code:2922509090

Physical and Chemical Properties:
Melting point:250°C
Boiling point:N/A
Density:3.38 g/mL at 25 °C(lit.)
Index of Refraction:
PSA:
Exact Mass:412.76800
LogP:2.75550

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3288 6.1/PG 3
Packing Group:I; II; III


Contact us for information like EINECS 233-050-9 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00011378 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00011378 Use and application,Potassium platinochloride technical grade,usp/ep/jp grade.


Related News: Overall, Wang confirmed that AZ can still grow its China business at low double digits in the second half of the year, but the company declined to offer an outlook for 2022. sodium 5-(3-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)propyl)benzo[d][1,3]dioxole-2,2-dicarboxylate manufacturers AstraZeneca’s deal, the largest struck last year, is all part of CEO Pascal Soriot’s mission to hit $40 billion in global sales by 2023. 4-(1-dimethylamino-ethylideneamino)-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester suppliers After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million. Bicyclo[6.1.0]non-9-yl-methyl-amine vendor & factory.